Sun Pharma said it plans to launch the product in the coming days in partnership with Hypera Pharma, a leading pharmaceutical company in Brazil. "The approval of semaglutide in Brazil expands access to an evidence-based treatment option for people living with inadequately controlled type 2 diabetes. According to IQVIA MAT June 2026 data cited by the company, the semaglutide injectable market in Brazil is valued at approximately USD 413 million. Sun Pharma is a global pharmaceutical company with operations spanning innovative medicines, generics, and consumer healthcare products. It is India's largest pharmaceutical company and has a significant presence in the U.S. generics market and other global emerging markets.